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Abstract
Background: Candida spp. are frequently cultured from the respiratory tract in critically ill patients. Most intensivists
start amphotericin-B deoxycholate (ABDC) inhalation therapy to eradicate Candida spp. from the respiratory tract.
However, the safety and efficacy of this treatment are not well established. The purpose of this study was to assess
the safety and efficacy of ABDC inhalation for the treatment of respiratory Candida spp. colonization in critically ill
patients.
Methods: All non-neutropenic patients admitted into the intensive care unit (ICU) of a university hospital from
December 2010–2011, who had positive Candida spp. cultures of the respiratory tract for more than 1 day and
required mechanical ventilation >48 h were retrospectively included. The decision to start ABDC inhalation had
been made by attending intensivists on clinical grounds in the context of selective decontamination of the
digestive tract. Infection characteristics and patient courses were assessed.
Results: Hundred and thirteen consecutive patients were studied. Fifty-one of them received ABDC inhalation and
their characteristics at baseline and day 1 of respiratory colonization did not differ from those of colonized patients
not receiving treatment (n = 62). The ABDC-treated group had a similar Candida spp. load but did not decolonize
more rapidly as compared to untreated patients. The clinical pulmonary infection and lung injury scores did not
decrease as in the untreated group. In a Cox proportional hazard model, the duration of mechanical ventilation was
increased (P < 0.003) by ABDC treatment independently of other potential determinants and Candida spp.
colonization. No differences in ventilator-associated pneumonia or in overall mortality (up to day 90) were observed.
Conclusion: Treatment of respiratory Candida spp. colonization in non-neutropenic critically ill patients by inhaled
ABDC may not affect respiratory colonization but may increase duration of mechanical ventilation, because of direct
toxicity of the drug on the lung.
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Background
In critically ill patients, Candida spp. are frequently cul-
tured from non-sterile body sites. However, the clinical
significance hereof is not easy to define. When Candida
spp. are isolated from the respiratory tract, discriminating
between relatively harmless colonization or invasive infec-
tion is still surrounded by controversy and leads to thera-
peutic dilemmas [1-8]. On the one hand, respiratory
isolation of Candida spp. could reflect the patient’s state
of immunoparalysis and the elimination of normal flora
through previous antibiotic treatment but may otherwise
be relatively harmless. On the other hand, it could reflect
a risk factor for invasive Candida spp. infections, even in
non-neutropenic patients, such as candidemia or pulmon-
ary candidiasis, a rare and difficult to diagnose deep infec-
tion in the critically ill [2,3]. Respiratory Candida spp.
colonization has also been suggested to be a risk factor for
(multidrug-resistant) Gram-negative airway infection, i.e.
ventilator-associated pneumonia (VAP) or tracheobron-
chitis, to prolong ventilator dependency and to increase
mortality, even in the absence of direct pulmonary patho-
genicity [6,9-11].
One way to examine the clinical role of Candida spp.
colonization of the respiratory tract is to examine the
effect of treatment aimed at eradicating the fungus. The
criteria to start antifungal drugs continue to be debated
[1,4]. Nevertheless, one study suggests that systemic anti-
fungal treatment may help to prevent Pseudomonas spp.-
associated VAP in the critically ill patient colonized by
Candida spp. in the respiratory tract [11]. Also, in neutro-
penic hematology patients at risk for invasive fungal infec-
tions inhalation therapy with liposomal amphotericin B
has been proven to prevent invasive pulmonary aspergil-
losis [12,13]. ABDC inhalation is also used to prevent pul-
monary aspergillosis in many lung transplant units but the
safety and efficacy of this approach has never been vali-
dated in a large randomized placebo-controlled trial.
Selective decontamination of the digestive tract (SDD) is
a strategy used in many Dutch intensive care units (ICU’s)
and consists of oral administration of non-absorbable anti-
biotics. When Candida spp. respiratory colonization is doc-
umented during routine surveillance cultures of the
respiratory tract and the patient is at risk for deep infection,
intensivists often start with amphotericin-B deoxycholate
(ABDC) inhalation therapy via a nebulizer. This treatment
is started as part of many SDD protocols used in large trials
[14,15]. However, its safety and efficacy are not well estab-
lished, in the absence of randomized trials [16]. In rats,
aerolized ABDC decreases activity of surfactant suggesting
a possibility to harm [17-19]. In humans, however, (liposo-
mal) amphotericin-B inhalation may not alter surfactant
but may be cytotoxic by other means [20,21].
To further elucidate the significance of Candida spp.
in respiratory secretions and the safety and efficacy of
ABDC inhalation therapy, we retrospectively compared
clinical courses of mechanically ventilated patients colo-
nized with Candida spp. in the respiratory tract which
received ABDC inhalation with those of a comparable
group of patients in which ABDC was not initiated. The
hypothesis was that ABDC is a safe and effective treat-
ment for Candida spp. colonization of the respiratory
tract and thereby prevents VAP and prolonged need for
mechanical ventilation during SDD in the ICU.
Methods
Patients
Data were retrospectively collected from our patient data
management system, according to a predefined checklist.
All patients >18 years of age requiring mechanical ventila-
tion >48 h in the ICU of the Erasmus Medical Center
Rotterdam, with at least 2 consecutive daily positive
Candida spp. cultures of the respiratory tract (throat, tra-
cheal aspirates or bronchoalveolar lavage), defining respira-
tory colonization, were included when admitted between
December 2010 and December 2011. The ICU is a tertiary
care mixed medical-surgical ICU with 2000 admissions per
year. Patients with neutropenia (leukocyte count <0.5 ×
109/L), positive blood cultures for Candida spp., immuno-
deficiency (HIV, solid cancer, hematologic malignancy,
solid- organ or bone marrow transplantation, or long term
or high dose steroid treatment) or who did not meet re-
spiratory colonization criteria were excluded (Figure 1). In-
formed consent was not needed according to the Dutch
law because of the retrospective analysis in which data col-
lected during routine clinical care were used and anonym-
ously treated.
Clinical protocol
Patients requiring mechanical ventilation for more than
48 h receive SDD in our unit. This involves administra-
tion of an oral paste, a suspension via the nasogastric
190 mechanically ventilated patients 
with positive Candida spp. cultures of 
the respiratory tract







- positive blood cultures with 
Candida spp. (n=9)
- colonization ≤1 day (n=68)
Figure 1 Patient inclusion. ABDC = amphotericin-B deoxycholate.
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tube and a suppository, containing the non- absorbable an-
tibiotics tobramycin, amphotericin B and colistin. For the
first three days, patients also receive cefotaxim intraven-
ously at 4 times 1 gram a day. At the start of SDD, cultures
are taken (inventory cultures) from throat, tracheal aspi-
rates, urine, rectum and drains or wounds. To monitor the
effect of the SDD, surveillance cultures (from throat, tra-
cheal aspirates, urine, and rectum) are done routinely three
times per week. SDD and surveillance cultures are contin-
ued until ICU death or discharge. On indication, additional
cultures of the respiratory tract are taken at the discretion
of the attending intensivist. Standard microbiological
methods were used to culture the specimens. For the pur-
pose of fungal detection in respiratory samples a Sabouraud
agar (SB), incubated at 26°C was used. A Gram strain was
performed to identify epithelial cells and bacteria. If the
Gram strain contained 10 times more leukocytes than epi-
thelial cells and if there were more than 6 species of one
type of microorganism the streaked agar plates were incu-
bated. Candida colonies are visually identified on the
Sabouraud agar and identified to the species level using
CHROMagar™. ABDC inhalation therapy is not part of the
standard of care SDD regimen but can be added at the dis-
cretion of the attending intensivist when tracheal aspirates
or throat cultures are repeatedly positive for Candida spp.
and the patient is considered to be at risk for deep infec-
tion. For this purpose ABDC, dissolved in dextrose 5% with
a final concentration of 10 mg/mL is nebulized in a Maquet
nebulizing system (Maquet Servo Ultra Nebulizer, Maquet,
Sweden), 4 times daily (daily dose 4 × 4 mL =40 mg).
ABDC inhalation therapy is discontinued after two con-
secutive daily respiratory tract cultures or after detubation
of the patient. Other antifungal therapy was instituted at
the discretion of the attending intensivist based on cultures
taken from other body sites. Pneumonia was diagnosed and
treated by the attending intensivist on the basis of clinical,
imaging and microbiological data in close collaboration
with the infectious disease specialists. VAP was defined as
the presence of a new or progressive pulmonary infiltrate
on the chest radiograph along with infectious signs such as
fever ≥38.5°C or ≤36.5°C, leukocyte count ≥10 × 109/L or
≤4 × 109/L and purulent tracheobronchial secretions [22].
Study protocol and data collection
At admission/baseline, demographic data and clinical vari-
ables, including age, sex, pre-morbidity, prior use of anti-
biotics including SDD and other risk factors for Candida
spp. colonization, antifungal treatment, steroids, immune
status (active malignancy or other causes of an immuno-
compromised state), reasons for admission, invasive pro-
cedures (arterial or venous central catheter, pulmonary
artery catheter, endotracheal intubation) and treatment of
organ failure (inotropic support, hemodialysis and mech-
anical ventilation settings) were recorded (but not all data
are shown when considered not contribute). The simpli-
fied acute physiology score (SAPS II) was computed at
admission. Day 1 of the study was defined as the first day
of respiratory colonization with Candida spp. The acute
physiology and chronic health evaluation II (APACHE II)
and the sequential organ failure assessment (SOFA) were
recorded at day 1. All cultures from the respiratory tract
were recorded from day 1 until day of decolonization, i.e.
the duration of respiratory colonization. Airway Candida
decolonization was defined as the first day of 2 consecu-
tive daily respiratory cultures negative for Candida spp. in
the ICU. Candida spp. load was calculated as the number
of positive respiratory cultures and the sum of the load
(in thousands of colonies) of the cultures divided by the
total cultures taken, using cultures from day 1 until
decolonization, ICU death or discharge, whatever came
first. Candida spp. load was classified as mild, <104, mod-
erate, 104-105, and severe, >105. For the ABDC-treated
group, the duration of respiratory colonization and load
were calculated from day 1 until start of ABDC and from
the start of ABDC until decolonization, ICU death or dis-
charge, whatever came first. In order to calculate the clin-
ical pulmonary infection score (CPIS) [23] at day 1 and 7,
routinely obtained temperature (°C), white blood cell
count (WBC, 109/L), amount of tracheal secretions, chest
radiography imaging results and PaO2/FIO2 ratio (kPa)
were recorded using the worse data recorded during the
24 hours of that day. At day 1 and 7, we also recorded
positive end-expiratory pressure (PEEP, cm H2O), ratio of
arterial PO2 to inspiratory O2 fraction (PaO2/FIO2, kPa),
total respiratory dynamic compliance (mL/cm H2O) and
chest radiography imaging results to calculate the lung in-
jury score (LIS) [24]. The compliance is calculated from
tidal volume and difference between in- and expiratory
pressures on the ventilator. The LIS is calculated by using
the worst physical data recorded during the 24 hours of
that day and the number of quadrants (0–4) on the chest
radiograph showing alveolar consolidations. Patients were
followed until day 28 and 90 after day 1 and duration of
ICU stay, duration of colonization and mechanical ventila-
tion (from day 1 until start of inhalational ABDC and
thereafter until detubation not requiring reintubation
within 48 h) and vital outcomes were recorded.
Statistical analysis
Continuous variables were expressed as the mean with
standard deviation (SD) or when the assumption of nor-
mality (Kolmogorov-Smirnov test P < 0.05) was violated
as median values and interquartile ranges. Since ABDC
treatment was started at median 5 days of colonization,
patients colonized for 5 days or more were selected from
the non-treated group for comparisons of durations.
Kaplan-Meier curves were constructed and log rank test-
ing was performed to evaluate group differences in
van der Geest et al. BMC Infectious Diseases 2014, 14:575 Page 3 of 9
http://www.biomedcentral.com/1471-2334/14/575
colonization and ventilation durations, censored for
death or discharge from the ICU. Multiple Cox propor-
tional hazard modeling was done to evaluate the effect
of ABDC treatment, irrespective of other variables asso-
ciated with mechanical ventilation. Hazard ratios (HR)
and 95% confidence intervals (CI) were calculated. All
tests were two-sided and P < 0.05 was considered statisti-
cally significant. Exact P values >0.001 are given.
Results
Characteristics of patients who received ABDC (n = 51)
and those who did not (n = 62) are summarized in Table 1.
There tended to be more males in the treated group, but
groups were otherwise comparable at baseline up to day 1,
suggesting similar general risks for respiratory Candida
spp. colonization. However, ABDC-treated patients had a
longer duration of stay in the ICU but mortality did not
differ from that in untreated patients.
Respiratory Candida spp. colonization, risk factors,
bacterial infection and treatment characteristics
according to ABDC inhalation treatment
Table 2 gives the data from day 1 of respiratory colonization
until ICU death or discharge for the untreated and treated
Table 1 Patient characteristics at admission, day 1 of colonization and clinical course
ABDC no n = 62 ABDC yes n = 51 P
Age, years 57 (17) 58 (20)s 0.62
Gender, male 34 (55) 37 (73) 0.05
Premorbidity
Cardiac 31 (50) 18 (35) 0.12
Gastointestinal 21 (34) 24 (47) 0.16
Cancer 17 (27) 16 (31) 0.65
Pulmonary 16 (26) 13 (25) 0.97
Neurological 11 (18) 12 (24) 0.45
DM 12 (19) 8 (16) 0.61
Renal 5 (8) 9 (18) 0.14
Immune 2 (3) 0 (0) 0.16
Other 20 (32) 14 (27) 0.58
Reasons of ICU admission 0.28
Suspected infection 18 (29) 18 (35)
Respiratory failure 9 (15) 13 (25)
Shock 9 (15) 6 (12)
Neurological 11 (18) 4 (8)
Medical 3 (5) 3 (6)
Postoperative 6 (9) 4 (8)
CPR 4 (6) 1 (2)
Trauma 2 (3) 2 (4)
SAPS II 43 (18) 48 (16) 0.12
At day 1 of colonization
APACHE II 21 (12) 20 (9) 0.21
SOFA 9 (6) 9 (5) 0.18
Days from admission ICU 1 (3) 1 (2) 0.64
Ventilation from admission, days 1 (2) 1 (3) 0.18
Course
Duration of stay ICU, days 10 (12) 24 (18) <0.001
28-day mortality 19 (32) 10 (20) 0.13
90-day mortality 27 (45) 19 (37) 0.40
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = amphotericin-B deoxycholate; DM = diabetes mellitus;
ICU = intensive care unit; CPR = cardiac pulmonary resuscitation; SAPS II = simplified acute physiology score; APACHE II = acute physiology and chronic health
evaluation II; SOFA = sequential organ failure assessment score.
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Table 2 Respiratory Candida spp. colonization, risk factors, bacterial infection and treatment characteristics starting day 1 of colonization in untreated group
and from day 1 of colonization to start of treatment in treated group and thereafter, until ICU death or discharge
ABDC no Day 1 until ICU death
or discharge, n = 62
ABDC yes Day 1 to start
treatment, n = 51
P vs no ABDC yes Day 1 until ICU
death or discharge, n = 51
P vs no
Total Candida spp. cultures respiratory tract 2 (1) 3 (1) 0.67 4 (3) <0.001
Candida spp. load 0.46 0.36
Mild, <104 38 (61) 32 (58) 30 (60)
Moderate, 104-105 13 (21) 18 (33) 16 (32)
Heavy, >105 11 (18) 5 (9) 4 (8)
Candida albicans 41 (66) 34 (61) 0.45 32 (63) 0.74
Candida non-albicans 3 (4) 1 (2) 3 (6)
Both Candida spp. 18 (30) 20 (37) 16 (31)
Duration of respiratory colonization, days 5 (9) 5 (5) 0.66 12 (18) <0.001
Corticosteroids 23 (37) 18 (35) 0.85 22 (43) 0.52
TPN 21 (34) 16 (31) 0.78 18 (35) 0.88
Ventilator-associated pneumonia, 23 (37) 11 (22) 0.16 18 (35) 0.96
Days after first Candida spp. culture 4(6) 3 (4) 0.43 5(4) 0.91
Gram positive 6 (10) 0 (0) 2 (4)
Gram negative 17 (27) 11 (22) 16 (31)
CPIS, day 1 7 (3) 8 (2) 0.10 NA NA
day 7 5 (4) NA NA 8 (3) <0.001
Systemic antifungal treatment 17 (27) 13 (26) 0.39 18 (35) 0.93
Echinocandins 11 (17) 9 (18) 11 (21)
Azoles 6 (10) 4 (8) 7 (14)
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = amphotericin-B deoxycholate; TPN = total parenteral nutrition; CPIS = clinical pulmonary infection score; day 1 and 7






















groups. Colonization lasted 5 (9) days in the untreated
group and ABDC was started 5 (5) days after the day of first
positive respiratory Candida spp. culture, so that we also
compared groups for these comparable time frames. The
data suggest similar risk and load of respiratory
colonization with Candida spp. until treatment is started
for both groups. However, the ABDC-treated group seemed
to have an overall higher load and prolonged colonization
than the untreated group, because of start of early and
spontaneous decolonization in the latter. The CPIS score
was higher 1 week after day 1 in the absence of more VAP
in treated patients. Conversely, there was no decrease in
the occurrence of VAP in the treated group. Even though
total Candida spp. cultures in the respiratory tract after
start of ABDC (1 (2)) was lower than before start (3 (1)) (P
< 0.001), respiratory colonization durations were similar,
from day 5 (untreated group) or start of treatment (ABDC-
treated group) to 28 days later (Figure 2).
Patient courses
Table 3 gives the ventilation characteristics for both
groups. The LIS and PaO2/FIO2 ratio at day 1 were simi-
lar between the groups, but at day 7 the LIS was higher
and the PaO2/FIO2 ratio was lower in the ABDC-treated
than untreated group. The PEEP was higher in the
ABDC-treated group at day 7. Patients receiving ABDC
were mechanically ventilated longer than patients with-
out treatment (Figure 3), from day 5 or start of treat-
ment onwards, in untreated and treated groups,
respectively. The effect of ABDC on mechanical
ventilation duration was independent from other factors
such as duration of colonization after day 5 and LIS on
day 7 (Table 4).
Discussion
This non-randomized observational study suggests that
ABDC inhalation by critically ill, mechanically ventilated
patients with respiratory Candida spp. colonization is
not effective and potentially harmful. Patients on ABDC
inhalation did not decolonize more rapidly, remained
mechanically ventilated for an additional 13 days and
had a longer ICU stay but no increased mortality, as
compared to untreated patients.
Our study suffers from a non-randomised design, so
that conclusions should be drawn carefully. Neverthe-
less, the data suggest that prior to start of treatment, dis-
ease severity, colonization risk and load were similar
among the groups. Treatment was started approximately
5 days after the first positive respiratory Candida spp.
culture, when in the untreated group spontaneous
decolonization had already started. We are therefore un-
certain, in disagreement with previous studies [16],
whether decolonization would have also occurred in the
treated group if treatment had been disadvised or post-
poned. However, when groups were matched for the
same duration of respiratory colonization prior to treat-
ment, no difference could be observed in rate of
decolonization (Figure 2), in contrast to the increase in
decolonization with treatment from 62 to 86% observed
in a previous, but larger, non-randomized study [16].
Figure 2 Duration of respiratory colonization from day 5 (now day 0 in graph) of colonization in untreated (continuous line) and from
start of amphotericin B (ABDC) on day 0 in graph in treated patients (dotted line) until negative cultures, censored for death or
discharge from the intensive care unit, to day 28; P = 0.45 (log-rank test).
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A previous study showed an incidence of VAP in pa-
tients with respiratory Candida spp. colonization of
24% which is comparable to the 29% incidence in this
study [9]. However, our data do not suggest that
Candida spp. colonization in the respiratory tract pre-
disposed to VAP, in contrast to studies suggesting that
this could promote VAP development, especially when
caused by Pseudomonas aeruginosa and multidrug
resistant bacteria [9,10]. Conversely, there is no
suggestion that respiratory decolonization was associ-
ated with less VAP, in contrast to suggestions that sys-
temic antifungal treatment decreases the incidence of
VAP [11]. The differences in ventilation durations
cannot be attributed to differences in the occurrence of
VAP, even though the relatively non-specific CPIS (as
well as the LIS) was higher on day 7 in the ABDC-
treated group, since the CPIS was not a determinant of
mechanical ventilation duration in multivariate analysis.
Table 3 Ventilation characteristics at day 1 and 7 of colonization
ABDC no n = 62 ABDC yes n = 51 P
Tidal volume, ml/kg, day 1 7 (2) 7 (2) 0.77
Tidal volume, ml/kg, day 7 7 (3) 8 (3) 0.50
PEEP, cm H2O, day 1 9 (4) 9 (4) 0.10
PEEP, cm H2O, day 7 6 (5) 10 (6) 0.004
Compliance, mL/cm H2O, day 1 37 (28) 44 (39) 0.05
Compliance, mL/cm H2O, day 7 40 (27) 41 (36) 0.09
PaO2/ FIO2 ratio, day 1 213 (122) 197 (137) 0.40
PaO2/ FIO2 ratio, day 7 282 (123) 217 (147) 0.005
Chest X-ray, no. of quadrants, day 1 2 (2) 2 (1) 0.27
Chest X-ray, no. of quadrants, day 7 2 (3) 2 (2) 0.41
LIS, day 1 2.0 (1.0) 1.8 (1.3) 0.47
LIS, day 7 1.0 (1.3) 1.8 (1.5) 0.002
Ventilation after day 1, days 7 (9) 20 (16) <0.001
Numbers (percentage) or median (interquartile range), where appropriate. Abbreviations: ABDC = amphotericin B deoxycholate; PEEP = positive end-expiratory
pressure; PaO2 = partial pressure of oxygen in the blood (kPa); FIO2 = the percentage of oxygen administered; LIS = lung injury score; day 1 and 7 refer to day of
first isolation of Candida spp. in respiratory secretions and 1 week later, respectively.
Figure 3 Duration of mechanical ventilation from day 5 (now day 0 in graph) of colonization in untreated (continuous line) and from
start of amphotericin B (ABDC) on day 0 in graph in treated patients (dotted line), censored for death or discharge from the intensive
care unit, to day 28; P = 0.003 (log-rank test).
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Safety issues of ABDC inhalation therapy remain a con-
cern [19,20]. We therefore looked at pulmonary injury
and ventilation durations, which appeared independent of
respiratory colonization duration in our patients. The lung
scores suggest greater injury in treated patients at day 7
already than in untreated patients, independent of VAP.
Two studies showed surfactant dysfunction by ABDC,
thereby deteriorating gas exchange [17,18], possibly via
direct inhibition or damage of the alveolar capillary mem-
brane resulting in an influx of surfactant-inactivating
plasma proteins. Loss of surfactant could lead to longer
requirement of mechanical ventilation in patients receiv-
ing inhalational ABDC. Indeed, the longer duration of
mechanical ventilation and thus ICU stay in our study in
ABDC-treated patients can be explained by pulmonary
adverse effects of the drug. Our data do not exclude that
ABDC inhalation prevents pulmonary infections with As-
pergillus spp. but suggests that it may carry pulmonary
toxicity.
Conclusions
In conclusion, treatment of pulmonary Candida spp.
colonization in non-neutropenic critically ill patients by in-
haled ABDC may not facilitate respiratory decolonization
but may increase duration of mechanical ventilation, be-
cause of direct pulmonary toxicity of the drug. Therefore,
inhalation of ABDC for respiratory colonization with Can-
dida spp. in non-neutropenic critically ill patients cannot
be recommended outside prospective randomized trials.
For the latter, the use of less toxic liposomal dissolved for-
mulation may be preferred [21,25].
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